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Background: Worldwide, a large proportion of neonates are prescribed antibiotics
without having infections leading to increased antimicrobial resistance, disturbance
of the evolving microbiota, and increasing the risk of various chronical diseases.
Comparing practice between different hospitals/settings is important in order to optimize
antibiotic stewardship.
Aim: To investigate and compare the potential for improved antibiotic stewardship in
neonates in two Norwegian hospitals with different academic culture, with emphasis on
antibiotic exposure in unconfirmed infections, treatment length/doses, CRP values and
the use of broad-spectrum antibiotics (BSA). All types of infections were investigated,
but the main focus was on early-onset sepsis (EOS).
Methods: We conducted a prospective observational cohort study of antibiotic use
in a Norwegian university hospital (UH) and a district hospital (DH), 2017. Unconfirmed
infections were defined as culture negative infections that neither fulfilled the criteria for
clinical infection (clinical symptoms, maximum CRP >30 mg/L, and treatment for at least
5 days).
Results: Ninety-five neonates at the DH and 89 neonates at the UH treated with
systemic antibiotics were included in the study. In total, 685 prescriptions (daily doses)
of antibiotics were given at the DH and 903 at the UH. Among term and premature
infants (≥ 28 weeks), 82% (75% at the UH and 86% at the DH, p = 0.172) of
the treatments for suspected EOS were for unconfirmed infections, and average
treatment length in unconfirmed infections was 3.1 days (both hospitals). Median dose
for aminoglycoside was higher for term infants at the UH (5.96, 95% CI 5.02–6.89)
compared to the DH (4.98, 95% CI 4.82–5.14; p < 0.001). At the UH, all prescriptions
with aminoglycosides were gentamicin, while tobramycin accounted for 93% of all
prescriptions with aminoglycosides at the DH.
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Conclusion: There is a potential for reduction in both antibiotic exposure and treatment
length in these two neonatal units, and a systematic risk/observational algorithm of sepsis
should be considered in both hospitals. We revealed no major differences between the
UH and DH, but doses and choice of aminoglycosides varied significantly.
Keywords: neonatal antibiotic use, antimicrobial resistance, pediatric antibiotic stewardship, antibiotic doses,
antibiotic prescriptions
INTRODUCTION
Unnecessary use of antibiotics leads to increased rates of
antimicrobial resistance (AMR) and is one of the main challenges
in global health (1, 2). AMR rates are low in Norway compared
to other countries but has increased during the last decade (3).
The Norwegian government has introduced a National Strategy
aiming for a 30% reduction in total antibiotic use, and a 30%
reduction in the use of broad-spectrum antibiotics (BSA) in
hospitals, by year 2020 (4).
Neonates and small children are particularly vulnerable to
antibiotic exposure as the diversity of the gut microbiota
increases and evolves during the first years of life (5). In
addition to increased resistance rates (6, 7), early life antibiotic
exposure is associated with the evolvement of various chronic
diseases (8–10).
Worldwide, neonates with suspected sepsis are exposed to
antibiotics, although only a small proportion have a confirmed
infection (11–13). The interpretation of risk factors, clinical
symptoms, and biomarkers is challenging, and may explain why
antibiotic exposure rates in neonates vary between hospitals, also
within the same countries (11, 14). A registry-based population
study fromNorway (2009–2011) showed that half of term-infants
receiving antibiotics were not proven to have a bacterial infection
(11). Use of BSA in Norwegian neonates is lower than in older
children, but empirical choices of antibiotics vary, and there is a
lack of evidence on neonatal dose regimes (15, 16).
Fifteen of the 68 hospitals registered in the database of The
Norwegian Institute of Public Health hold a neonatal unit; seven
of these units are situated in university hospitals while the rest
are situated in smaller district hospitals (all are public hospitals).
The university hospitals hold many academic positions and are
expected to be in the frontline of developing clinical practice.
We therefor speculate whether there are any clearly differences in
antibiotic use between centrally located university hospitals and
more rural located district hospitals.
The aim of this study was to explore antibiotic use among
neonates with and without confirmed infection, with emphasis
on choice and dosing of antibiotics, treatment duration, CRP
values and the use of BSA. Furthermore, we assessed whether
pattern of antibiotic use in neonates differs between university
and district hospitals.
Abbreviations: UH, University hospital, DH, District hospital; AMR,
Antimicrobial resistance; BSA, Broad-spectrum antibiotics; GA, Gestational
age; CNS, Central nervous system.
METHODS
Setting and Design
We designed a prospective observational cohort study, collecting
data from 2017 to describe and compare antibiotic use in
neonates in a Norwegian university hospital (UH) (Oslo
University Hospital, Ullevål) and a district hospital (DH)
(Ålesund Hospital).
Hospitals
The study population consisted of all neonates admitted to the
neonatal units at the UH and the DH in the study periods. The
DH has a neonatal intensive care unit (NICU) consisting of 13
beds and provides regional neonatal service for neonates from
gestational age (GA) 26 weeks (after centralization of infants
below 26 weeks to a regional UH from February 2017) and
offers all kinds of intensive care apart from neonatal surgery and
ECMO. The UH has a NICU consisting of 27 beds and provides
regional service for neonates with all GA ages and all intensive
care needs apart from ECMO and thoracic/heart surgery. Both
hospitals mainly treat neonates admitted from the maternity
ward, but at the DH critically ill infants (<3month) can in certain
circumstances be referred to the neonatal unit from home.
There are no official national guidelines for antibiotic
treatments in neonates in Norway, and most hospitals have
local guidelines. In 2017, both study hospitals recommended
the use of an aminoglycoside in combination with ampicillin
for the treatment of early-onset sepsis. For term infants,
the UH recommended aminoglycoside to be dosed 6 mg/kg
as one daily administration, while the DH recommended 5
mg/kg. Both hospitals recommended ampicillin to be dosed
50 mg/kg two times a day. None of the hospitals used
specific algorithms/observations routines for deciding whether
to start antibiotic therapy once neonatal sepsis was suspected.
The communication between the laboratory and the neonatal
departments is well-established in both hospitals, and both
results fromCRP analyses and blood cultures are easy and rapidly
available for the treating clinicians. In both hospitals, positive
blood cultures are alerted directly from the microbiologist in
terms of a personal call to the on-duty physician.
Data Collection
At the DH, data were collected from 1st of January−31st of
December, 2017. The collection was performed by trained nurses
working at the unit and double-checked by the project manager.
At the UH, data were collected during 15 weeks in 2017; from
27th of March−20th of May and from 01st of November−31th of
December. Data were collected by two MD‘s working at the unit
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and the quality control was performed by the project manager.
Educational classes for data collectors were held before the start
of the registration.
In both hospitals, patients receiving antibiotics were identified
at 08.00 a.m. by the collectors every morning by evaluating
all inpatients. In these neonatal wards, outpatient treatment of
infections is very uncommon, thus we only included inpatients.
For registrations we modified and extended an international
standardized point prevalence protocol developed by the
European Center for Disease Prevention and Control (ECDC)
(17). The data were stored in an electronical database.
Data collection included the total number of patients in the
wards, the total number of patients receiving antibiotics, gender,
GA at birth, birthweight, delivery mode, age and weight at the
start of antibiotic treatment, type and dose (including intervals)
of antibiotics, route of administration, treatment duration (in
days), whether it was for treatment of infection or prophylaxis,
indication for treatment/prophylaxis, respiratory support (any
kind), maximum CRP value and results from blood cultures. For
patients receiving antibiotics at the start or end of the registration
period we obtained information from previous/remaining days of
antibiotic treatment.
The total numbers of live births in the uptake area for
both hospitals were collected from the maternity ward and also
controlled with the Norwegian birth registry.
Variables and Definitions
Term-infants were defined as GA ≥ 37 weeks, premature infants
as GA 28–36 weeks and extremely premature infants as GA 23–
27 weeks. All prescribed antibiotics were included in our analyses
and described in relation to prescriptions, administrations,
courses, and admitted patients. One prescription was defined as
a daily dose with one antibiotic, an administration was defined
as one single dose with one antibiotic, and a course was defined
as antibiotic therapy/prophylaxis with one or more antibiotics
for a certain indication in a certain continuous time range.
Each patient registered at the wards during the daily registration
was regarded as one bed day. Doses in mg/kg were based on
birthweight until a higher body weight was recorded, and we only
compared doses in term infants. Treatment duration was defined
as number of days with antibiotic exposure. The total number
of live births was used as a denominator for expressing antibiotic
exposure within the first 3 days of life. Antibiotics were defined as
antibacterials for systemic use (J01). Broad-spectrum antibiotics
were defined as second- and third-generation cephalosporins,
carbapenems, piperacillin/tazobactam and quinolones, according
to the National Strategy against AMR (4).
Surgical prophylaxis was defined as antibiotics given
immediately before, during or shortly after surgery to prevent
infection. Medical prophylaxis was defined as antibiotics
prescribed to prevent infection in patients at risk, but without
infectious symptoms and without obtainment of blood culture.
Cases where symptoms could be explained by infections, but
also by other conditions (for instance prematurity, asphyxia)
were not regarded as prophylaxis. Early-onset sepsis (EOS) was
defined as suspected sepsis within the first 3 days of life and
late-onset sepsis (LOS) when sepsis was suspected after 3 days of
life. Other indications were only used if organ specific symptoms
were present (such as skin infections) without suspected sepsis.
In theory, all infant with clinical symptoms and exposure for
blood culture were classified as sepsis treatments.
Treatments for suspected sepsis were divided in three
categories: Culture positive sepsis (which required a positive
blood culture and clinical symptoms), culture negative sepsis and
no sepsis. The first two categories were regarded as confirmed
infections. According to recommendations from the Norwegian
Neonatal Network, the diagnosis of a culture negative neonatal
sepsis (International Classification of Diseases, 11th revision,
P36.9), should only be used if certain criteria are fulfilled;
clinical symptoms, CRP >30 mg/L, at least 5 days of antibiotic
therapy (or death before 5 days) and whenever other medical
conditions are ruled out (18). Thus, we only included neonates
with CRP >30 and with at least 5 days of antibiotic treatment
(or death before 5 days) when defining culture negative neonatal
sepsis. According to the same recommendations, growth of
coagulase-negative Staphylococci in blood culture were only
considered as neonatal sepsis with CRP>10 and at least 5 days of
antibacterial therapy (or death before 5 days). The same method
was used to measure CRP in both hospitals: Particle enhanced
immune turbidimetry.
Statistics
Statistical analyses were performed using SPSS Statistics 23
(SPSS Inc., Chicago, IL, USA). Comparisons of proportions
were done using standard chi-square tests. Means and medians
were compared using independent samples t-test and Moods
median test, respectively. 95% confidence intervals of means were
calculated assuming normal distribution, whereas confidence
intervals of medians were calculated using the binomial
distribution. Correlation was estimated using Pearson correlation
coefficient. P-values <0.05 were considered significant. Because
the DH discontinued their service for extremely premature
infants with GA < 26 weeks during the study period, antibiotic
use in extremely premature infants (GA<28 week) was described
without comparisons.
Ethics
The study was approved by the Regional Committee for Medical
andHealth Research Ethics (2017/30/REKMidt) and by the Local
Data Protection Officials at the two hospitals.
RESULTS
Demographics and Characteristics
In total, 184 patients received 207 courses and
1,588 prescriptions of antibiotics. See Table 1 for
comparisons of demographics and characteristics between
the hospitals.
Antibiotic Prescriptions
For term and premature infants, aminoglycosides, and ampicillin
accounted for the majority of antibiotic prescriptions, namely
84% at the UH and 85% at the DH (See Figure 1). Use
of BSA was low (4.3% in total for both hospitals), but the
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TABLE 1 | Characteristics of neonates receiving antibiotics in two different Norwegian neonatal units in 2017.
Total University Hospital District Hospital p-valuea
ALL
Patients, n 593 235 358
Patients exposed to antibiotics, n (%) 184 89 (38) 95 (27) n/a
Courses with antibiotics, n 208 108 100
Prescriptions with antibiotics, n 1,588 903 685
Bed days with antibiotics/total bed days (%, 95% CI) 856/5,486 (16) 492/2,714 (18, 17–19) 364/2,772 (13, 12–14) n/a
Antibiotic exposure first 3 days/number of live births (%, 95% CI) 150/4,772 (3.1, 2.6–3.6) 73/2,091 (3.5, 2.7–4.3) 77/2,681 (2.9, 2.3–3.5) n/a
TERM INFANTS
Patients on antibiotics, n (%) 106 (58) 39 (44) 67 (71) n/a
Courses with antibiotics, n (%) 108 (52) 40 (37) 68 (69) n/a
Prescriptions with antibiotics, n (%) 769 (48) 301 (33) 468 (68) n/a
Prophylaxis/treatments, % of courses 4.6/95.4 7.5/92.5 2.9/97.1 0.278
Male/Female, % of patients 67/33 72/28 64/36 0.401
Cecirian delivery/vaginal delivery, % of patients 25/72 31/62 22/78 0.228
GA (weeks), mean (SD) 39.8 (1.7) 40.1 (2.0) 40.0 (1.6) 0.821
Weigh at start of treatment (g), mean (SD) 3,798 (616) 3,823 (615) 3,774 (616) 0.701
Antibiotic exposure first 3 days/number of live births (%, 95% CI) 92/4,470 (2.1, 1.7–2.5) 36/1,967 (1.8, 1.2–2.4) 56/2,503 (2.2, 1.6–2.8) 0.346
PREMATURE INFANTS
Patients on antibiotics, n (%) 40 (22) 16 (18) 24 (25) n/a
Courses with antibiotics, n (%) 42 (20) 17 (16) 25 (25) n/a
Prescriptions with antibiotics, n 281 (18) 127 (14) 154 (22) n/a
Prophylaxis/treatments, % of courses 10/90 5.8/94.2 8.0/92.0 0.670
Male/Female, % of patients 58/42 38/62 71/29 0.041
Cecirian delivery/vaginal delivery, % of patients 65/30 50/38 75/25 0.253
GA (weeks), mean (SD) 32.1 (2.4) 31.5 (2.3) 32.7 (2.6) 0.172
Weigh at start of treatment (g), mean (SD) 1,872 (747) 1,481 (537) 2,115 (758) 0.004
Antibiotic exposure first 3 days / number of live births (%, 95% CI) 32/269 (12, 8–16) 13/95 (14, 7–21) 19/174 (11, 6–16) 0.471
EXTREMELY PREMATURE INFANTSb
Patients on antibiotics, n (%) 38 (21) 34 (38) 4 (4)
Courses with antibiotics, n (%) 58 (28) 51 (47) 7 (7)
Prescriptions with antibiotics, n (%) 538 (34) 475 (53) 63 (9)
Antibiotic exposure first 3 days / number of live births (%) 26/33 (79) 24/29 (83) 2/4 (50) n/a
aA chi square test was used for proportions and Student’s t-test for means. N/A means that statistic testing was not appropriate because of case mix differences between the hospitals.
bThe DH only treated infants with GA < 28 weeks between 1th of January and 15th of February.
• GA, Gestational age.
• Term infants (≥ 37 weeks), premature infants (28–36 weeks), extremely premature infants (23–27 weeks).
• Missing data: Delivery mode on three patients (GA>37 weeks) and two patients (GA 28–37 weeks) at the University hospital, weight at one patient (GA >37 weeks) and two patients
(28–37 weeks) at the University hospital.
proportion of prescriptions was significantly higher at the DH
vs. the UH; 34 prescriptions (5.5%) vs. 11 prescriptions (2.6%),
respectively (p = 0.023), see Table 2 for more information.
Out of seven BSA courses prescribed at the DH, three were
given for LOS, two for lower respiratory tract infection,
one for EOS and one for infection in the CNS. Three of
these patients received respirator treatment, and three were
premature infants. The one course of BSA that was prescribed
at the UH were given for EOS to a term infant receiving
respirator treatment.
For extremely premature infants, aminoglycosides
and ampicillin accounted for 57% of the prescriptions
(both hospitals), and BSA use accounted for 15%. For
all neonates, 119 (96%) of in total 124 prescriptions with
BSA were second or third generation cephalosporins and
5 (4%) were carbapenems. At the UH, all prescriptions
with aminoglycosides were gentamicin, while tobramycin
accounted for 93% of all prescriptions with aminoglycosides at
the DH.
Startup of Antibiotics
Hundred and twenty-four (83%) out of 150 courses of antibiotics
for term and premature infants were started during the first
3 days of life in both hospitals; day one (107, 71%), day two
(10, 7%), day three (7, 5%). Table 2 shows that prescription rate
in relation to starting time of the course varied significantly
between the hospitals. For extremely premature infants, 29
(50%) out of 58 courses were started within the first 3 days
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FIGURE 1 | Distribution of antibiotic prescriptions in two Norwegian neonatal units. Broad- spectrum antibiotics are defined as second- and third generation
cephalosporins and carbapenems.
of life, 4 (7%) between day three and ten and 25 (43%) after
day ten.
Indications for Antibiotic Courses
For term and premature infants, treatment of suspected EOS
accounted for 121 (81%) out of 150 antibiotic courses without
significant difference between the hospitals (78% at the UH
and 84% at the DH, p = 0.452). The remaining courses
were given for LOS (7%), organ-specific infections without
suspected sepsis (7%) and prophylaxis (5%). See Table 2 for
detailed information about the various indications.Table 3 shows
characteristics in treatments of confirmed and unconfirmed
EOS among term and premature infants, and highlights that a
high number of treatments were given for unconfirmed EOS.
Median treatment duration for unconfirmed EOS was 3 days
both for term and premature infants and without significant
difference between the hospitals (Table 3). The maximum CRP
value (mean) and the confident intervals increased parallel to the
number of treatment days (Figure 2). The estimated correlation
coefficient was 0.64 (p < 0.001). Among extremely premature
infants, EOS accounted for 28 (48%) out of 58 antibiotic
courses, late-onset sepsis (LOS) for 24 (41%) of the courses
and prophylaxis for 6 (10%) of the courses. Mean treatment
duration was 4.25 days, 95% CI 3.49–5.01 (EOS + LOS).
Figure 3 shows that a much higher proportion of infants received
treatment for confirmed infections among extremely premature
infants. See Supplemental Digital Content 1 for more detailed
characteristics of the extremely premature infants. In total, two
patients died during their antibiotic therapy (one at the UH and
one at the DH).
Blood Cultures
The rate of blood cultures obtained before initiation of treatments
for sepsis (all GA groups) was 99% (171/173). Among term and
premature infants, four (two EOS and two LOS) out of 128
(3.1%, 95% CI 0.0–6.2) treatments for suspected sepsis revealed
a positive blood culture, corresponding to 0.8/1,000 live born
infants. For EOS, the numbers needed to treat for one positive
blood culture was 60. Among extremely premature infants, 14
(2 EOS and 12 LOS) out of 52 (27%, 95% CI 13–35) treatments
for sepsis included a positive blood culture (12 at the UH and
2 at the DH), corresponding to 14 out of 38 (37%) of extremely
premature infants in the units. Figure 3 clearly illustrates that the
proportion of blood culture positive infections was much higher
for extremely premature infants.
Overall, the bacteria growing in the cultures were coagulase
negative Staphylococcus (8), Streptococcus agalactiae (5),
Staphylococcus aureus (3), and Escherichia coli (2). Mean
treatment duration for infections with coagulase negative
Staphylococcus was 7.0 days. Five of the treatments involved
vancomycin supplemented with one or more of the following
antibiotics: aminoglycoside, ampicillin, cloxacillin or
ceftazidime. One treatment involved only Cefotaxim and
the two last treatments involved an aminoglycoside combined
with ampicillin in one case and cloxacillin in the other.
Mean treatment duration for infections with Streptococcus
agalactiae was 9.3 days. Two of the treatments involved mainly
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TABLE 2 | Distribution of antibiotic exposure in two Norwegian neonatal units (GA







Courses, n 150 57 93




45 (4.3) 11 (2.6) 34 (5.5) 0.023
Courses including
BSA, n (%)
8 (5.3) 1 (1.8) 7 (7.5) 0.128
0–3 DAYS
Coursesc, n (%) 124 (83) 49 (86) 75 (81) 0.405
Prescriptions,
n (%)
861 (82) 369 (86) 492 (79) 0.003
BSA prescriptions,
n (%)
15 (1.7) 11 (3.0) 4 (0.8) 0.019
Courses including
BSA, n (%)
2 (1.6) 1 (2.0) 1 (1.3) 0.761
3–10 DAYS
Coursesd, n (%) 14 (9) 6 (11) 8 (9) 0.695
Prescriptions,
n (%)
113 (11) 51 (12) 62 (10) 0.317
BSA prescriptions,
n (%)
10 (9) 0 (0) 10 (16) 0.002
Courses including
BSA, n (%)
2 (14) 0 (0) 2 (25) 0.202
>10 DAYS
Coursese, n (%) 12 (8.0) 2 (3.5) 10 (11) 0.114
Prescriptions,
n (%)
76 (7.2) 8 (1.9) 68 (11) <0.001
BSA prescriptions,
n (%)
20 (26) 0 (0) 20 (29) 0.102
Courses including
BSA, n (%)
4 (33) 0 (0) 4 (40) 0.294
aChi square test.
bBSA: Broad-spectrum antibiotics are defined as second-and third generation
cephalosporins and carbapenems.
cUniversity hospital (UH) treatment: early onset sepsis (48), UH prophylaxis: maternal
syphilis (1).
District hospital (DH) treatment: Early onset sepsis (73), DH prophylaxis: central catheter
line (1), vesicourethral reflux (1).
dUH treatment: late onset sepsis (3), eye-infection (1). UH prophylaxis; vesicourethral
reflux (2).
DH treatment: infection in skin, joint and bone (4), late-onset sepsis (3). DH prophylaxis:
surgery of transposition of the great vessels (1).
eUH prophylaxis: tracheostomia (1), unknown (1).
DH treatment: Late onset sepsis (4), lower respiratory tract infection (3), infection in bone,
joint and skin (2), CNS infection (1).
benzylpenicillin (partly in combination with an aminoglycoside),
two treatments involved an aminoglycoside combined with
ampicillin in one case and cloxacillin in the other, and one
case involved a combination of vancomycin, ceftazidime, and
metronidazole. Mean treatment duration for infections with
Staphlococcus aureus was 8.3 days. Two of the treatments
consisted of cloxacillin monotherapy for more than half of the
course and the last case involved an aminoglycoside combined
with ampicillin and cloxacillin. For treatment of Escherichia
coli, one patient was treated with an aminoglycoside combined
with ampicillin for 8 days. The other patients, that was treated
with an aminoglycoside and ampicillin the first to days and
with cefotaxime monotherapy the third day, died during the
treatment period. Among the other patients with culture positive
sepsis, no fatalities or relapse of infections were registered during
the study period.
Doses
Among term infants treated with antibiotics during the first week
of life, significantly higher doses of aminoglycosides were used at
the UH compared to the DH (Table 4). Moreover, the number of
daily administrations for ampicillin was higher at the DH.
DISCUSSION
This study reveals that only 1/5 of treatments for suspected
EOS in term and premature infants were confirmed infections.
Average treatment length for unconfirmed infections was just
above 3 days. No significant differences were observed between
the hospitals for characteristics of EOS, but doses and choice of
aminoglycosides varied between the hospitals.
A strength of this study is the prospective design, that only
a few collectors performed the registrations and the small share
of missing data. Other studies have excluded coagulase-negative
Staphylococci from epidemiological overviews of positive blood
cultures because of the probability of contamination (11, 19).
Since we included both the treatment length and the CRP values
in our data collection, we could apply the definition from the
Norwegian Neonatal Network to decide whether or not to regard
these as “true” positive cultures (18). An advantage of using
an observational cohort design instead of a point-prevalence
survey is the lower risk for casualties like ongoing epidemics,
to influence the results. Furthermore, our design gives access
to variables that requires continuously observational data for
the entire treatment period of an antibiotic course. However, a
disadvantage with long period registrations is the challenge and
feasibility to include more than just a few hospitals.
An important limitation is the low power of the study to detect
clinically relevant differences between the hospitals. We aimed to
include extremely premature infants also from the DH, but this
could not be done due to unexpected hospital centralization for
infants with GA < 26 weeks during the study period. Another
limitation is the lack of data on maternal risk factors for EOS.
We did nor register whether patients were admitted from home,
from other hospitals or from the maternity ward; as described in
methods we could speculate that some patients at the DH were
admitted from home reflected by the significantly higher number
of term and premature infants >10 days when initiating their
antibiotic course. The data collection was performed by clinicians
and nurses working at the respective wards, and most clinicians
were aware of the study. This may have affected the data in the
manner of more prudent antibiotic use than usual. However, as
this possible bias was the same in both hospitals it would not
affect the comparison between the hospitals. Our sampling did
neither report the name of the clinicians prescribing antibiotics.
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TABLE 3 | Characteristic in treatment of early-onset sepsis (EOS) in two Norwegian neonatal units, gestational age (GA) ≥ 28 weeks.
All University Hospital District Hospital P-valuea
ALL
EOS treatments, n 121 48 73
Confirmed EOSb, n (%, 95% CI) 21 (17, 10–24) 11 (23, 11–35) 10 (14, 6–22)
Unconfirmed EOS, n (%, 95% CI) 99 (82, 75–89) 36 (75, 63–87) 63 (86, 78–94)
Unknown (%) 1 (0.8) 1 (2) 0 (0) 0.172
TERM INFANTS (GA ≥ 37 WEEKS)
EOS treatments, n (%) 91 (75) 36 (75) 55 (75) 0.966
CONFIRMED EOS
Treatments, n (%, 95% CI) 21 (23, 14–32) 11 (31, 16–46) 10 (18, 8–28) 0.173
Treatment duration, mean (95% CI) 5.95 (5.4–6.5) 6.1 (5.3–6.9) 5.8 (5.3–6.3) 0.586
Maximum CRP, mean (95% CI) 61.1 (52.4–69.8) 61.0 (48.4–73.6) 61.3 (49.5–73.1) 0.975
Bloodcultures obtained, n (%) 21 (100) 11 (100) 10 (100) n/a
Positive bloodcultures, n (%, 95% CI) 2c (10, 0–14) 1 (10, 0–14) 1 (10, 0–14) 0.945
Respiratory support, n (%) 5 (24) 4 (36) 1 (10) 0.169
UNCONFIRMED EOS
Treatments, n (% 95% CI) 70 (77, 68–86) 25 (69, 54–84) 45 (82, 72–92) 0.173
Treatment duration, mean (95% CI) 3.01 (2.7–3.3) 3.16 (2.39–3.93) 3.0 (2.72–3.28) 0.709
Maximum CRP, mean (95% CI) 17.3 (12,9–21,5) 18.2 (12.0–24.5) 16.8 (11.6–22.9) 0.751
Bloodcultures obtained, n (%) 69 (99) 24 (96) 45 (100) 0.357
Respiratory support, n (%) 28 (40) 11 (44) 17 (38) 0.613
PREMATURE INFANTS (28–36 WEEKS)
EOS treatments, n (%) 30 (25) 12 (25) 18 (25) 0.966
CONFIRMED EOS
Treatments, n (%) 0 (0) 0 (0) 0 (0) n/a
UNCONFIRMED EOS
Treatments, n (%, 95% CI) 29 (97, 91–103) 11 (92, 77–107) 18 (100, 100) 0.221
Treatment duration, mean (95% CI) 3.03 (2.6–3.5) 3.36 (2.52–4.21) 2.83 (2.39–3.28) 0.313
Maximum CRP, mean (95% CI) 8.6 (4.1–13.1) 5.9 (−0.65–12.45) 10.2 (3.42–17.02) 0.305
Bloodculture obtained, n (%) 28 (97) 11 (100) 17 (94) 0.434
Respiratory support, n (%) 20 (69) 8 (73) 12 (67) 0.737
UNKNOWN
Treatments, n (%) 1 (3.3) 1 (8.3) 0 (0) 0.222
aChi square test was used for proportions and Student’s t-test for means. For “all treatments,” p-value was based on chi square test for all variables in the section.
bPositive blood culture or CRP > 30 and minimum 5 days of treatment (or death before 5 days). Bloodcultures with Coagulase-negative staphylococci (CoNS) were considered positive
if CRP > 10 and minimum 5 days of treatment (or death before 5 days).
cOne case of Streptococcus agalacticae (GBS) at the University hospital and one case of Staplylococcus epidermidis at the District hospital.
It is reasonable to assume that prescription habits are difficult to
change in a manner that would have a significantly impact on our
results, but a minor bias can not be excluded. Finally, different
registration periods at the two hospitals may have introduced
a bias in relation to the seasonality of certain pathogens. One
study concluded that there was no seasonal variation in the
prevalence of gram-negativemicrobes causing LOS (20). Another
study showed a prevalence of viral infections of 1% at admitted
neonates in a neonatal unit (21). Viral infections are known for
their seasonality and may have created an imbalance in the two
registrations that should be taken into account as they often lead
to antibiotic use in infants. However, both hospitals have strict
infection control and isolation routines at their neonatal wards,
and our main objective of this study was nor to describe the
prevalence of infections.
For term and premature infants, use of BSA was low in both
hospitals, but the number of prescriptions was higher at the DH.
This can partly be explained by four children at the DH receiving
BSA after 10 days of age compared to zero at the UH. Also, three
of the seven BSA treatments at the DH was for other indications
than sepsis and three of the infants were critically ill in term
of receiving respirator treatment. One could speculate whether
doctors at the UH have a higher threshold for prescribing BSA
than in the DH, but taking the low numbers of BSA treatments
into account, this difference is probably not clinically relevant.
However, this finding should be controlled in future studies.
The difference in the doses of aminoglycosides in term infants
is explained by different local guideline recommendations at the
hospitals. We did not register any switch of aminoglycoside doses
in term infants during the same course, and one study showed
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that aminoglycosides safely can be dosed 6 mg/kg every 24 h
in term born infants (22). The higher number (mean) of daily
administrations with ampicillin at the DH may be explained
by the recommendation in a commonly used local Norwegian
neonatal supervisor to increase the number of administrations
from two up to four per day in severe infections/meningitis
(23). From our data, we can not conclude whether there was
a difference in severity between the hospitals. More studies
focusing on therapeutic drug monitoring of antibiotics in
neonates should be conducted in order to optimize dose regimes
in the future (24).
The choice of aminoglycoside differed in the UH (gentamicin)
and the DH (tobramycin) because of different local guidelines.
One study found lower creatinine levels in neonates treated
with tobramycin compared to gentamicin, but concluded that
the clinical significance of the findings were minimal (25).
Tobramycin is the preferred antibiotic to treat infections caused
by Pseudomonas aeruginosa (26), but this pathogen is rarely
detected in the Norwegian infant population (11, 27). As
tobramycin is more expensive than gentamicin, the latter can be
argued as the aminoglycoside of choice for neonates. By exploring
the local hospital guideline at the DH, we could not find any
specific reasons (such as local data on microbiological resistance
patterns) that would support the use of tobramycin, and from
2018 the DH started to recommend the use of gentamicin
as first choice aminoglycoside, partly because of this review
of practice.
The rate of antibiotic exposure during the first 3 days of life
in term infants is in line with national data from 2009 to 2011
(11), 2.1 and 2.2%, respectively. This indicates no significant
change in antibiotic exposure during the last 6 years. However,
our rate is low, compared to international literature (28–30).
The relation between culture-positive and culture-negative sepsis
(term infants, EOS) in our population (1:10) is in the published
range (31), while the numbers needed to treat for one positive
culture [60] is at the lower side of the literature (11, 32). Our rate
of antibiotic exposure for extremely premature infants is in line
with data from the USA (33).
We found that 77% of antibiotic courses to term infants
for suspected EOS were given to infants without confirmed
infections, compared to 54% in the previous national survey
(11). In the national survey all antibiotic exposures (including
prophylaxis) was included, but only two term infants in our
study received prophylactic courses. Also, criteria for culture
negative sepsis varied, as the national survey did not include CRP
values in the evaluation, and therefore may have overestimated
the incidence of confirmed infections. Among premature infants,
we observed no confirmed infections in any of the hospitals,
indicating a lower threshold for antibiotic therapy. Several studies
show that introduction of an algorithm/observational based risk
stratification strategy for neonatal sepsis can reduce antibiotic use
(30, 34).
Mean treatment duration for unconfirmed EOS (term infants)
was shorter than in the national survey from 2009 to 2011, 3
(mean) vs. 4 days (median), respectively. Extremely premature
infants in our study were averagely treated 4 days (EOS+LOS).
The probability of positive blood cultures beyond 24–48 h is small
FIGURE 2 | Mean maximum CRP level (n = 120) in relation to number of
treatment days (GA ≥ 28 weeks) among Norwegian hospitalized neonates.
(35), and studies indicate that treatment safely can be withdrawn
after 48 h when clinical suspicion is low (36, 37).
We found that maximum CRP values and 95% CI increased
with number of treatment days, indicating that CRP values are
regarded as an important factor when deciding treatment length.
A recently published study showed that CRP values >30 was
uncommon in healthy term infants, supporting the decision of
using 30 as cut of level for infection (38). Other biomarkers are
also used, but available evidence has not concluded which to
prefer (39).
In choice of antibiotics, adherence to local hospital guidelines
was high and the use of BSA was low. Previous studies
show that several Norwegian hospitals use benzylpenicillin
instead of ampicillin in empirical treatments combined with an
aminoglycoside (11, 16, 40), and this variation is also present
world-wide (41). High prevalence of Listeria monocytogenes
could justify the use of ampicillin, but according to data from
The Norwegian Institute of Public Health, only four cases of
listeriosis have been reported among Norwegian children (< 1
year) from 2011 to 2018 (42). Use of ampicillin combined with
gentamicin may increase the selection of resistant gram negative
bacteria in neonatal units (43). A randomized controlled trial
comparing the two regimes found no difference in efficiency
or in gut disturbance, but it was underpowered to detect
clinical differences (44). Nevertheless, since benzylpenicillin
has a narrower antibacterial spectrum probably leading to
a lower risk of gut disturbance and resistance, we suggest
both study hospitals to consider benzylpenicillin instead of
ampicillin in their local guidelines. The commonly used local
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FIGURE 3 | Treatments for early-onset sepsis and late-onset sepsis in two Norwegian neonatal units differentiating between confirmed and unconfirmed infections
proportionally.
TABLE 4 | Doses of aminoglycosides and ampicillin among term born infants first
10 days of life in two Norwegian neonatal units, 2017.


























37, 100 (98.48–101.52) 55, 100
(93.89–106.11)
0.248
aStudent’s t test was used for means and Mood median test for medians.
bNumber of single doses of antibiotics given within 24 h.
cDH: Ten daily doses were administered in three daily administrations and one daily dose
was administered in four daily administrations (all were 0–3 days old). UH: All daily doses
were administered in two daily administrations.
• No switch of daily doses was registered for any of the antibiotics during one
single course.
(but national available) Norwegian neonatal supervisor also
recommends benzylpenicillin on behalf of ampicillin. At the
DH, this change was performed in their local guidelines
during 2018.
The definition of medical prophylaxis in neonates is
complicated and not well-established. We introduce a definition
combining symptoms and the obtainment of blood culture
(there is no need for blood culture if the purpose is to
prevent an infection) to rule out prophylaxis. Even though
we speculate that blood cultures in some cases are taken
as part of an implemented routine, our results show a low
use of antibiotic prophylaxis in both hospitals compared to
international data (41).
The number of extremely premature infants with a positive
blood culture (37% of all extremely premature infants in the
units, EOS and LOS), is in line with international reports (45, 46).
It confirms the need for new strategies to prevent infections in
these vulnerable neonates. However, one study identified that one
third of extremely premature infants had low risk of EOS and
possibly could avoid exposure to antibiotics (47).
Our results can be used in future antibiotic stewardship
programs, including research projects, in Norwegian
neonatal departments, for instance by introducing
interventions/algorithms to reduce antibiotic exposure and
treatment duration. A unified national guideline including clear
antibiotic recommendations and dose regimes is desirable.
For future surveillances, we have suggested a definition
of prophylaxis.
CONCLUSION
Based on our study there are no indications of major differences
in the pattern of antibiotic use between university and district
hospitals in Norway, but term infants at the UH were
treated with higher doses of aminoglycosides and fewer daily
administrations of ampicillin. Furthermore, gentamicin was the
aminoglycoside of choice at the UH, while tobramycin was
mainly used at the DH. Even though neonates in Norway
receive less antibiotic than in other countries, this study revealed
that there is a potential for reduction in both antibiotic
exposure and treatment duration for neonates. A systematic
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risk/observational stratification of sepsis should be considered in
both hospitals.
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